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ABSTRACT
Pyruvate kinase is an essential enzyme in the anaerobic glycolytic pathway of the erythrocyte. 
The clinical presentation of this enzyme deficiency is due to the haemolytic process that results 
from the inability  of erythrocytes  to  generate sufficient  ATP. Although pyruvate  kinase and 
glucose-6-phosphate dehydrogenase deficiencies comprise more than 90% of all reported red cell 
enzyme disorders worldwide, the epidemiology of the disease in South Africa is unknown and 
there is no assay for pyruvate kinase activity currently being used in South Africa. This report 
describes the implementation of screening and quantitative assays for pyruvate kinase activity in 
the Red Cell Membrane Unit at the University of the Witwatersrand Medical School / NHLS. 
The accuracy,  precision and reproducibility of the assay were verified. Furthermore, a patient 
with  pyruvate  kinase  deficiency  was  confirmed and  found  to  have  15% of  normal  enzyme 
activity  at  37oC.  The  genetic  abnormality  was  identified  as  a  homozygous  G1529A  point 
mutation in exon 11 of the pyruvate kinase gene and to the candidate’s knowledge is the first 
mutation described in a South African kindred. The patient’s mother was heterozygous for the 
G1529A mutation and demonstrated an enzyme activity of 58% of normal at 37oC. 
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